Neupro use extended

The licence for Neupro (rotigotine) transdermal patch has been extended to include use as an adjuvant to levodopa therapy for advanced Parkinson's disease.

Neupro can be used in combination with levodopa over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or 'on-off' fluctuations).

A single daily dose should be initiated at 4mg/24h and then increased in weekly increments of 2mg/24h to an effective dose up to a maximum of 16mg/24h. For most patients an effective dose is reached within three to seven weeks. Neupro was launched in April 2006 for the treatment (as monotherapy) of early idiopathic Parkinson's disease signs and symptoms.

Further information: Schwarz Pharma 01923 684100
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases